DIVIS LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of DIVIS LABORATORIES have increased by 19.31% YoY .
The Earnings Per Share (EPS) of DIVIS LABORATORIES has increased by 36.93 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
DIVIS LABORATORIES Last 5 Annual Financial Results
[BOM: 532488|NSE : DIVISLAB]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹9,360 Cr | ₹7,845 Cr | ₹7,767 Cr | ₹8,960 Cr | ₹6,969 Cr |
| Expenses | ₹6,391 Cr | ₹5,639 Cr | ₹5,398 Cr | ₹5,079 Cr | ₹4,108 Cr |
| Operating Profit (Excl OI) | ₹2,969 Cr | ₹2,206 Cr | ₹2,369 Cr | ₹3,881 Cr | ₹2,861 Cr |
| Other Income | ₹352 Cr | ₹339 Cr | ₹345 Cr | ₹116 Cr | ₹63 Cr |
| Interest | ₹3.00 Cr | ₹4.00 Cr | ₹2.00 Cr | ₹2.00 Cr | ₹2.10 Cr |
| Depreciation | ₹402 Cr | ₹378 Cr | ₹343 Cr | ₹312 Cr | ₹256 Cr |
| Profit Before Tax | ₹2,916 Cr | ₹2,163 Cr | ₹2,369 Cr | ₹3,684 Cr | ₹2,666 Cr |
| Profit After Tax | ₹2,191 Cr | ₹1,600 Cr | ₹1,824 Cr | ₹2,960 Cr | ₹1,984 Cr |
| Consolidated Net Profit | ₹2,191 Cr | ₹1,600 Cr | ₹1,824 Cr | ₹2,960 Cr | ₹1,984 Cr |
| Earnings Per Share (Rs) | ₹82.68 | ₹60.38 | ₹68.83 | ₹111.53 | ₹74.75 |
| PAT Margin (%) | 23.29 | 20.28 | 23.33 | 32.94 | 28.38 |
| ROE(%) | 15.35 | 12.15 | 14.89 | 28.16 | 23.90 |
| ROCE(%) | 20.45 | 16.46 | 19.36 | 35.06 | 32.07 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 175,725.2 Cr |
| Revenue (TTM) | : | ₹ 9,360.0 Cr |
| Net Profit(TTM) | : | ₹ 2,191.0 Cr |
| EPS (TTM) | : | ₹ 82.5 |
| P/E (TTM) | : | 80.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| DIVIS LABORATORIES | -1.1% | 0.1% | 45.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.4% | 1.8% | 4.5% |
| CIPLA | 3.8% | 1.2% | -1.1% |
| TORRENT PHARMACEUTICALS | 2.2% | 11.7% | 11.7% |
| DR REDDYS LABORATORIES | 1.4% | -3.3% | -7.2% |
| MANKIND PHARMA | -1.7% | 13% | 22.9% |
| ZYDUS LIFESCIENCES | 0.7% | -0.6% | -17.7% |
| LUPIN | 1.5% | 1.3% | 7% |
| AUROBINDO PHARMA | -1.4% | -0.1% | -17.7% |
DIVIS LABORATORIES Revenues
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | 19.31 % |
| 5 Yr CAGR | 7.65 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹9,360 Cr | 19.31 | |
| Mar2024 | ₹7,845 Cr | 1.00 | |
| Mar2023 | ₹7,767 Cr | -13.31 | |
| Mar2022 | ₹8,960 Cr | 28.56 | |
| Mar2021 | ₹6,969 Cr | - | |
DIVIS LABORATORIES Operating Profit
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | 34.59 % |
| 5 Yr CAGR | 0.93 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹2,969 Cr | 34.59 | |
| Mar2024 | ₹2,206 Cr | -6.88 | |
| Mar2023 | ₹2,369 Cr | -38.96 | |
| Mar2022 | ₹3,881 Cr | 35.65 | |
| Mar2021 | ₹2,861 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 12.80 % |
| 5 Yr CAGR | -6.24 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 31.72% | 12.80 | |
| Mar2024 | 28.12% | -7.80 | |
| Mar2023 | 30.5% | -29.59 | |
| Mar2022 | 43.32% | 5.53 | |
| Mar2021 | 41.05% | - | |
DIVIS LABORATORIES Profit After Tax
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | 36.94 % |
| 5 Yr CAGR | 2.51 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹2,191 Cr | 36.94 | |
| Mar2024 | ₹1,600 Cr | -12.28 | |
| Mar2023 | ₹1,824 Cr | -38.39 | |
| Mar2022 | ₹2,960 Cr | 49.19 | |
| Mar2021 | ₹1,984 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 14.84 % |
| 5 Yr CAGR | -4.82 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 23.29 % | 14.84 | |
| Mar2024 | 20.28 % | -13.07 | |
| Mar2023 | 23.33 % | -29.17 | |
| Mar2022 | 32.94 % | 16.07 | |
| Mar2021 | 28.38 % | - | |
DIVIS LABORATORIES Earnings Per Share (EPS)
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | 36.93 % |
| 5 Yr CAGR | 2.55 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹83 | 36.93 | |
| Mar2024 | ₹60 | -12.28 | |
| Mar2023 | ₹69 | -38.29 | |
| Mar2022 | ₹112 | 49.20 | |
| Mar2021 | ₹75 | - | |
DIVIS LABORATORIES Return on Capital Employed (ROCE)
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | 24.24 % |
| 5 Yr CAGR | -10.64 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 20.45% | 24.24 | |
| Mar2024 | 16.46% | -14.98 | |
| Mar2023 | 19.36% | -44.78 | |
| Mar2022 | 35.06% | 9.32 | |
| Mar2021 | 32.07% | - | |
DIVIS LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹6,618.7 |
| Current MarketCap | : | ₹ 175,725.2 Cr |
| Updated EOD on | : | Jul 25,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | -1.1% |
0.1% |
45.6% |
| SENSEX | -0.4% |
-1.6% |
1.3% |
DIVIS LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE MOMENTUM INDEX | 0.6% | 0.3% | -3.3% |
| BSE HEALTHCARE | 0.5% | 4% | 17% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY HEALTHCARE INDEX | 1.2% | 4.1% | 12.6% |
| NIFTY100 ALPHA 30 | 1% | -0.8% | -8.9% |
| NIFTY PHARMA | 0.3% | 3.9% | 9.2% |
| NIFTY200 ALPHA 30 | -0.1% | -1.6% | -8.6% |
| NIFTY100 ESG | -0.3% | -1% | 0.6% |
You may also like the below Video Courses
FAQ about DIVIS LABORATORIES Financials
How the annual revenues of DIVIS LABORATORIES have changed ?
The Revenues of DIVIS LABORATORIES have increased by 19.31% YoY .
How the Earnings per Share (EPS) of DIVIS LABORATORIES have changed?
The Earnings Per Share (EPS) of DIVIS LABORATORIES has increased by 36.93 % YoY .
Check out Intrinsic Value of Peers of DIVIS LABORATORIES
Compare Stock Analytics of Peers of DIVIS LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
